AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been assigned an average rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $4.38.

Several equities analysts have commented on the stock. Seaport Global Securities restated a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Friday, October 6th. B. Riley started coverage on shares of AVEO Pharmaceuticals in a research report on Monday, November 13th. They set a “buy” rating and a $5.00 price objective for the company. started coverage on shares of AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, BidaskClub cut shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th.

AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $3.10 on Friday. The company has a market cap of $366.75, a price-to-earnings ratio of -4.37 and a beta of 1.14. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $4.24.

Institutional investors have recently added to or reduced their stakes in the company. Fore Research & Management LP purchased a new stake in shares of AVEO Pharmaceuticals during the 2nd quarter worth $111,000. Victory Capital Management Inc. purchased a new stake in shares of AVEO Pharmaceuticals during the 3rd quarter worth $164,000. Rehmann Capital Advisory Group purchased a new stake in shares of AVEO Pharmaceuticals during the 3rd quarter worth $193,000. OxFORD Asset Management LLP purchased a new stake in shares of AVEO Pharmaceuticals during the 3rd quarter worth $228,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of AVEO Pharmaceuticals during the 3rd quarter worth $550,000. 50.91% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “AVEO Pharmaceuticals, Inc. (AVEO) Given Average Recommendation of “Hold” by Brokerages” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/aveo-pharmaceuticals-inc-aveo-given-average-recommendation-of-hold-by-brokerages/1806374.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.